Seizure Management in Cancer Patients
Levetiracetam is the first-line antiepileptic drug for cancer patients who have experienced a seizure, while prophylactic anticonvulsants should NOT be routinely prescribed in seizure-free patients with brain tumors. 1, 2
Initial Assessment and Diagnosis
When a cancer patient presents with new-onset seizures:
- Obtain contrast-enhanced brain MRI immediately to rule out intracranial neoplasm or identify tumor progression 1
- Consider EEG to rule out nonconvulsive status epilepticus if there are worsening neurological symptoms or altered vigilance 1
- Evaluate alternative etiologies: treatment-related neurotoxicity, infections, paraneoplastic syndromes, metabolic disturbances, or cerebrovascular disease 1
Critical caveat: In patients with known brain tumors, worsening seizure control often signals tumor progression—repeat MRI even without other neurological changes 1
Acute Seizure Management
For patients presenting with active seizures:
- Benzodiazepines are first-line for acute seizure control and status epilepticus 3
- Stabilize with supportive care and address any metabolic derangements
- For emergent situations with significant mass effect, surgical decompression may be the immediate priority 4
Antiepileptic Drug Selection
First-Line Treatment
After a first seizure in a cancer patient, initiate levetiracetam 1. This recommendation is based on:
- Efficacy in seizure control (72% of European neuro-oncologists consider it most effective) 5
- Favorable side-effect profile 1
- No enzyme induction—critical to avoid interactions with chemotherapy and steroids 1, 6
- Availability of IV formulation for acute situations 7
Psychiatric side effects remain a concern with levetiracetam—screen for pre-existing psychiatric comorbidities before initiation 1, 8
Alternative First-Line Options
If levetiracetam is contraindicated or not tolerated:
- Lamotrigine: Good antiseizure activity but requires several weeks to reach therapeutic levels 1
- Lacosamide: Increasingly used as monotherapy or add-on therapy 1, 8
- Valproic acid: Efficacious with good tolerability, but:
Drugs to AVOID
Do NOT use enzyme-inducing anticonvulsants 1, 6:
- Phenytoin
- Phenobarbital
- Carbamazepine
These drugs cause significant interactions with steroids, cytotoxic agents, and targeted therapies (including irinotecan, gefitinib, erlotinib, temsirolimus), compromising cancer treatment efficacy 1, 6
Prophylactic Anticonvulsants: NOT Recommended
Primary prophylaxis is NOT indicated 1, 2, 9:
- Level I evidence shows prophylactic AEDs do NOT reduce first seizure risk in brain tumor patients 1
- This applies to both surgical and non-surgical patients 2, 9
- If started perioperatively, discontinue within the first postoperative week in seizure-free patients 4, 2
The evidence is unequivocal: prophylaxis causes unnecessary side effects (cognitive impairment, psychiatric symptoms, fatigue, drug interactions) without benefit 2
Secondary Prophylaxis (After First Seizure)
The vast majority of brain tumor patients who experience a seizure should receive anticonvulsant treatment, at least transiently 1:
- Continue until local tumor control is achieved through surgery, radiation, or chemotherapy 1
- After near-gross total resection without recurrence: Attempt tapering within weeks post-surgery 1
- After partial resection with subsequent tumor regression: Tapering can be considered 1
Dosing Considerations
While specific dosing is not extensively detailed in the guidelines, the principles are:
- Use monotherapy at the lowest effective dose 4
- Monitor serum levels to assess compliance and investigate treatment failure 1
- Titrate based on seizure control and tolerability
Drug Interaction Management
This is critical in cancer patients:
- Non-enzyme-inducing AEDs (levetiracetam, lamotrigine, lacosamide) minimize interactions with chemotherapy 1, 4, 6
- Valproic acid interactions must be checked regularly 1
- Closely monitor for adverse effects when combining AEDs with chemotherapy 6
Refractory Seizures
For seizures not controlled by monotherapy:
- Lacosamide as add-on treatment is gaining acceptance 1, 8
- Other options include briviracetam and perampanel 8
- Tumor-directed therapy (surgery, radiation, chemotherapy) can improve seizure control independent of tumor mass reduction 1, 7
Follow-Up and Monitoring
- Question patients about seizure occurrence at every visit 1
- Check AED serum levels to assess compliance and investigate breakthrough seizures 1
- Consider AED withdrawal in seizure-free patients after successful tumor treatment with good long-term prognosis 1, 7—79% of European neuro-oncologists routinely consider this 5
Common Pitfalls to Avoid
- Do not prescribe prophylactic AEDs in seizure-free patients—this is ineffective and harmful 1, 2
- Avoid enzyme-inducing AEDs at all costs—they compromise cancer treatment 1
- Do not use valproic acid in women of childbearing potential 1
- Screen for psychiatric history before starting levetiracetam 1, 8
- Do not continue perioperative AEDs beyond one week in seizure-free surgical patients 4, 2